Literature DB >> 8328966

The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

J Ghiso1, E Matsubara, A Koudinov, N H Choi-Miura, M Tomita, T Wisniewski, B Frangione.   

Abstract

The amyloid fibrils deposited in Alzheimer's neuritic plaque cores and cerebral blood vessels are mainly composed of aggregated forms of a unique peptide, 39-42 amino acids long, named amyloid beta (A beta). A similar, although soluble, A beta ('sA beta') has been identified in cerebrospinal fluid, plasma and cell supernatants, indicating that it is normally produced by proteolytic processing of its precursor protein, amyloid precursor protein (APP). Using direct binding experiments we have isolated and characterized an 80 kDa circulating protein that specifically interacts with a synthetic peptide identical with A beta. The protein was unmistakably identified as SP-40,40 or ApoJ, a cytolytic inhibitor and lipid carrier, by means of amino acid sequence and immunoreactivity with specific antibodies. Immunoprecipitation with anti-SP-40,40 retrieved soluble A beta from cerebrospinal fluid, indicating that the interaction occurs in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328966      PMCID: PMC1134315          DOI: 10.1042/bj2930027

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  50 in total

1.  SP-40,40 is a constituent of Alzheimer's amyloid.

Authors:  N H Choi-Miura; Y Ihara; K Fukuchi; M Takeda; Y Nakano; T Tobe; M Tomita
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Alzheimer beta/A4-amyloid precursor protein: evidence for putative amyloidogenic fragment.

Authors:  S E Gandy; R Bhasin; T V Ramabhadran; E H Koo; D L Price; D Goldgaber; P Greengard
Journal:  J Neurochem       Date:  1992-01       Impact factor: 5.372

3.  Processing of the amyloid protein precursor to potentially amyloidogenic derivatives.

Authors:  T E Golde; S Estus; L H Younkin; D J Selkoe; S G Younkin
Journal:  Science       Date:  1992-02-07       Impact factor: 47.728

4.  SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges.

Authors:  L Kirszbaum; S E Bozas; I D Walker
Journal:  FEBS Lett       Date:  1992-02-03       Impact factor: 4.124

5.  Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.

Authors:  T Wisniewski; B Frangione
Journal:  Neurosci Lett       Date:  1992-02-03       Impact factor: 3.046

6.  Amyloid beta-peptide is produced by cultured cells during normal metabolism.

Authors:  C Haass; M G Schlossmacher; A Y Hung; C Vigo-Pelfrey; A Mellon; B L Ostaszewski; I Lieberburg; E H Koo; D Schenk; D B Teplow
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

7.  Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Authors:  P Seubert; C Vigo-Pelfrey; F Esch; M Lee; H Dovey; D Davis; S Sinha; M Schlossmacher; J Whaley; C Swindlehurst
Journal:  Nature       Date:  1992-09-24       Impact factor: 49.962

8.  Identification of a stable fragment of the Alzheimer amyloid precursor containing the beta-protein in brain microvessels.

Authors:  A Tamaoka; R N Kalaria; I Lieberburg; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

9.  Distribution of clusterin in Alzheimer brain tissue.

Authors:  P L McGeer; T Kawamata; D G Walker
Journal:  Brain Res       Date:  1992-05-08       Impact factor: 3.252

10.  Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems.

Authors:  L Kirszbaum; J A Sharpe; B Murphy; A J d'Apice; B Classon; P Hudson; I D Walker
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  74 in total

1.  Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Authors:  C Haas; P Cazorla; C D Miguel; F Valdivieso; J Vázquez
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Links between the pathology of Alzheimer's disease and vascular dementia.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Yong-sheng Li; David Quartermain; Karen Duff; Thomas Wisniewski
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

3.  Preferential interactions between ApoE-containing lipoproteins and Aβ revealed by a detection method that combines size exclusion chromatography with non-reducing gel-shift.

Authors:  Mary Jo LaDu; Gregory W Munson; Lisa Jungbauer; Godfrey S Getz; Catherine A Reardon; Leon M Tai; Chunjiang Yu
Journal:  Biochim Biophys Acta       Date:  2011-11-23

4.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

Authors:  T Mitsuhashi; Y M Li; S Fishbane; H Vlassara
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 5.  The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy.

Authors:  Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2012-01-25       Impact factor: 5.590

6.  CSF proteomic analysis in patients with normal pressure hydrocephalus selected for the shunt: CSF biomarkers of response to surgical treatment.

Authors:  Antonio Scollato; Alessandro Terreni; Anna Caldini; Benedetta Salvadori; Pasquale Gallina; Simona Francese; Guido Mastrobuoni; Giuseppe Pieraccini; Gloriano Moneti; Luca Bini; Gianni Messeri; Nicola Di Lorenzo
Journal:  Neurol Sci       Date:  2009-11-21       Impact factor: 3.307

7.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

8.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

9.  Genetic variability in CLU and its association with Alzheimer's disease.

Authors:  Rita J Guerreiro; John Beck; J Raphael Gibbs; Isabel Santana; Martin N Rossor; Jonathan M Schott; Michael A Nalls; Helena Ribeiro; Beatriz Santiago; Nick C Fox; Catarina Oliveira; John Collinge; Simon Mead; Andrew Singleton; John Hardy
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

10.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.